The Mitochondria-Targeted Drug Development Digital Summit is the only industry-led meeting focused on end-to-end mitochondria-targeting. Explore success stories from leading experts overcoming common challenges whilst exploring what’s next to help you accelerate your pipeline into the clinic.

With 20+ hours of content, 2 interactive workshops and over 5 hours of networking with key industry leaders from Larimar Therapeutics, Minovia Therapeutics, Mitokinin and many more, this comprehensive forum will completely focus on mitochondria-targeting drug development and the current challenges and opportunities in the field.

Make this your 2021 must-attend meeting and network with 80+ senior CSOs, CEOs, research scientists, academics and investors committed to targeting mitochondria to tackle challenges with Mitochondrial & Age-related Diseases.

In this focused summit, you’ll learn from the field’s pioneers who’ll be sharing their experience in:

• Exploring the role of mitochondrial dysfunction in age-related diseases & rare genetic mitochondrial diseases
• Examining early discovery and research findings
• Evaluating preclinical drug development and studies
• Discovering the patient perspective to aid mitochondria-targeted drug development
• Assessing clinical development and showcasing current trials
• Lessons learned from clinical trial design and how design can be improved to mitigate common challenges
• Realizing the use of gene therapy, editing technology and innovation

To know more about Mitochondria-Targeted Drug Development Digital Summit please click here.